Angiotensin-converting enzyme inhibitors for ovarian cancer? - a new adjuvant option or a silent trap.

Katarzyna RegulskaMarcin MichalakTomasz KolendaJoanna Kozłowska-MasłońKacper GuglasBeata Stanisz

Published in: Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology (2023)

Available data warrant further research into repositioning ACE-Is to ovarian cancer as chemosensitizers. Prior to this, however, a special research program is needed to detect possible genotoxic contaminants of ACE-Is.

Keyphrases

angiotensin converting enzyme
angiotensin ii
early stage
electronic health record
quality improvement
drinking water
data analysis